Nautilus Biotechnology (NAUT) Accumulated Expenses (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Accumulated Expenses data on file, last reported at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 7.55% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (up 7.55% YoY), and the FY2025 full-year result was $3.2 million, up 24.69% from the prior year.
• Accumulated Expenses climbed to $3.3 million in Q1 2026, from $3.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $4.3 million in Q3 2023 to a low of $2.5 million in Q4 2024.
• A 5-year average of $3.4 million and a median of $3.4 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses jumped 136.17% in 2022 and slumped 35.41% in 2024, its largest moves.
• Tracing NAUT's Accumulated Expenses over 5 years: stood at $3.5 million in 2022, then increased by 11.82% to $3.9 million in 2023, then tumbled by 35.41% to $2.5 million in 2024, then advanced by 24.69% to $3.2 million in 2025, then gained by 4.03% to $3.3 million in 2026.
• Business Quant data shows NAUT's Accumulated Expenses at $3.3 million in Q1 2026, $3.2 million in Q4 2025, and $3.9 million in Q3 2025.